Comment on Kronenfeld et al. Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable. Cancers 2021, 13, 3814.

Markus Notter,Emanuel Stutz,Andreas R Thomsen,Peter Vaupel,Attila Kollár

doi:10.3390/cancers13225707

Abstract

On 2 July 2021, Kronenfeld et al. [...].

Highlights

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations
On 2 July 2021, Kronenfeld et al [1] published an excellent analysis of the clinical outcomes of primary angiosarcomas of the breast (PAS) and radiation-associated angiosarcomas of the breast (RAASB) treated with multimodality therapy in the last decade (2010–2020)
In a similar timeframe as the aforementioned analysis (2011–2021), we have focused on new treatment strategies for RAASB for recurrent tumors, which have the worst prognosis

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. On 2 July 2021, Kronenfeld et al [1] published an excellent analysis of the clinical outcomes of primary angiosarcomas of the breast (PAS) and radiation-associated angiosarcomas of the breast (RAASB) treated with multimodality therapy in the last decade (2010–2020). They concluded, that a multimodal treatment approach that included neoadjuvant chemotherapy (NAC), radiation therapy (RT) in selected patients, surgery (S), and adjuvant chemotherapy (AC) may result in improved outcomes, including prolonged survival.

Results

Conclusion